110 results
Page 4 of 6
6-K
EX-99
xakr05477 3t
9 Feb 15
2015 Annual General Meeting of Shareholders
12:00am
6-K
EX-99
3ng8yhyum yjq
5 Nov 14
BioLineRx Announces Successful Final Results of
12:00am
6-K
EX-99
s23zxa 8p0okre
21 Aug 14
BioLineRx Receives Notice of Allowance for US Patent on BL-7010
12:00am
6-K
EX-99
2zkt09m
16 Jul 14
BioLineRx Announces Results from
12:00am
6-K
EX-1
44x37
23 Jun 14
Current report (foreign)
12:00am
424B2
iy0jvowq
13 Jun 14
Prospectus for primary offering
12:00am
6-K
EX-1
8qqe zdloklc40hbn
11 Jun 14
Current report (foreign)
12:00am
6-K
EX-1.1
uajplt6doxd3cjqbui
30 May 14
Current report (foreign)
12:00am
F-3
gyswy alunvyp40ljh37
30 May 14
Shelf registration (foreign)
12:00am
6-K
EX-99
dw5hk8h
10 Mar 14
BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study
12:00am
6-K
EX-1.1
q3aw gh3clhg9
7 Mar 14
BioLineRx Closes $24.1 Million Underwritten Public Offering
12:00am
424B5
5wmhzlces04e3
4 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
oqpkh00ocft898ox
3 Mar 14
Prospectus supplement for primary offering
12:00am
6-K
EX-99
ov3kw702i2nb2y 2ow
18 Dec 13
Current report (foreign)
12:00am
6-K
EX-99
gmxl 7w633rdao55q
4 Nov 13
BioLineRx Receives Regulatory Approval to Commence
12:00am
6-K
EX-99
2roh11eefcb
24 Sep 13
BioLineRx Announces Regulatory Submission for Phase
12:00am
6-K
EX-99
lnsyhcx uv2t
19 Aug 13
BioLineRx Appoints B. J. Bormann to
12:00am
424B3
c653wck
8 Aug 13
Prospectus supplement
12:00am